MiSL also predicted ACACA to be a SL partner of the IDH1 mutation in glioma: along with the mutual exclusion between IDH1 mutation and ACACA deletions in pan-cancer data, ACACA was found to be overexpressed in glioma samples with the IDH1 mutation as compared to IDH1 wild-type samples (P value=0.008, Student's t-test). Here, ACACA is linked to central nervous system cancer.